Print Page  Close Window

SEC Filings

OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
Table of Contents

consultant working with Eli Lilly, Compellis Pharmaceuticals and Hypnion. He is a member of the Society for Neuroscience, CINP, and has academic appointments in the Department of Psychiatry at Indiana University’s School of Medicine and in Pharmacology at the Butler University’s College of Pharmacy and Health Sciences. Mr. Bymaster has a B.S. degree in Pharmacy from Butler University and an M.S. degree in Pharmacology from Indiana University.
James C. Lancaster, Jr. has served as our Vice President of Commercial Operations since August 2006. Previously, Mr. Lancaster was most recently a marketing consultant from March 2004 to August 2006 for Alkermes, Inc., G and S Research, Corcept Therapeutics, Neuronetics and Eli Lilly, among others. He continues in his role as a marketing consultant with Neuronetics, Devonport and Pamlab. Mr. Lancaster has broad commercial experience in the pharmaceutical industry, having started off in June 1971 at the individual retail level as the owner and store manager of his own pharmacy. From September 1977 to December 1999, he served as Sales Representative, Brand Manager of Prozac and Global Marketing Director of Zyprexa, and finally, from January 2000 to February 2003, the Director of Commercial Affairs for Eli Lilly’s Global Neuroscience division. In these roles, Mr. Lancaster was responsible for working with advocacy, clinical, regulatory and sales groups. Mr. Lancaster has a B.S. degree in Pharmacy from the University of Tennessee.
Board of Directors
Eckard Weber, M.D. is one of our co-founders and has served as a member of our board of directors since our inception in September 2002, and as the chairman of our board of directors since March 2004. Dr. Weber is also a partner at Domain Associates, L.L.C., a private venture capital management firm focused on life sciences, a position he has held since 2001. Dr. Weber has been a founder, founding chief executive officer and board member of multiple biopharmaceutical companies in the Domain portfolio including Cytovia, Inc., Acea Pharmaceuticals, Inc., NovaCardia, Inc., Novalar Pharmaceuticals, Inc., Novacea, Inc., Domain AntiBacterial Acquisition Corporation, Ascenta Therapeutics, Inc., Konova, Inc., Renovia, Inc., Tragara Pharmaceuticals, Syndax Pharmaceuticals and Tobira Therapeutics, Inc. Dr. Weber is currently a member of the board of directors of Novacea, Inc., a publicly held biopharmaceutical company, and he currently serves as interim Chief Executive Officer of Tramoxia Therapeutics, Inc., an early-stage biopharmaceutical company. He is also a current board member of Biovascular, Inc., Ocera, Inc., and Diobex, Inc. Dr. Weber holds a B.S. from Kolping College in Germany and an M.D. from the University of Ulm Medical School in Germany.
Louis C. Bock has served as a member of our board of directors since April 2005. Mr. Bock is a Managing Director of Scale Venture Partners, a venture capital firm. Mr. Bock joined Scale Venture Partners in September 1997 from Gilead Sciences, Inc., a biopharmaceutical company, where he held positions in research, project management, business development and sales from September 1989 to September 1997. Prior to Gilead, he was a research associate at Genentech, Inc. from November 1987 to September 1989. He currently serves as a director of Ascenta Therapeutics, diaDexus Inc., SGX Pharmaceuticals, Inc., Horizon Therapeutics and Zogenix, Inc. and is responsible for Scale Venture Partners’ investments in Prestwick Pharmaceuticals and Somaxon Pharmaceuticals. Mr. Bock received his B.S. in Biology from California State University, Chico and an M.B.A. from California State University, San Francisco.
Brian H. Dovey has served as a member of our board of directors since January 2004. Mr. Dovey is a managing member of Domain Associates, L.L.C., a private venture capital management firm focused on life sciences, and has served in this capacity with the firm since 1988. He has served as chairman of three companies and on the board of directors of approximately 30 additional companies, including Align Technology, Inc. and Cardiac Science, Inc. Mr. Dovey currently serves on the board of Neose Technologies, Inc., a publicly traded company. Prior to joining Domain, Mr. Dovey spent six years at Rorer Group, Inc. (now Aventis), including as president from 1986 to 1988. Previously, he was president of Survival Technology, Inc., a start-up medical products company. He also held management positions with Howmedica, Inc., Howmet Corporation, and New York Telephone. Mr. Dovey has served as both president and chairman of the National Venture Capital Association. He is Chair of the Wistar Institute, a non-profit preclinical biomedical research company. Mr. Dovey is also Co-Dean of the Kauffman Fellows Program at the Center for Venture Education.